Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02136836

Acronym

HER2

Enrollment

860

Registered

2014-05-13

Start date

2014-05-31

Completion date

Unknown

Last updated

2014-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach Neoplasms

Keywords

Genes, erbB-2, Prognosis

Brief summary

The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Histologically confirmed gastric adenocarcinoma 2. Patients were diagnosed during 2006-2013 3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.

Exclusion criteria

* Patients with second primary cancer within 5 years

Design outcomes

Primary

Measure	Time frame
The proportion of HER2 overexpression in gastric cancer patients	8 years

Secondary

Measure	Time frame
Gastric cancer specific survival according to HER2 expression in each stage	5 years

Other

Measure	Time frame
The practice pattern of Herceptin use in stage IV gastric cancer	3 years

Countries

South Korea

Outcome results